LC
CRL icon

Lindbrook Capital’s Charles River Laboratories CRL Stock Holding History

Lindbrook Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$72.6K Buy
482
+322
+201% +$54K 0.01% 824
2024
Q4 		$29.5K Sell
160
-4
-2% -$771 ﹤0.01% 1061
2024
Q3 		$32.3K Buy
164
+50
+44% +$10.4K ﹤0.01% 1026
2024
Q2 		$23.6K Hold
114
– – ﹤0.01% 1152
2024
Q1 		$30.9K Buy
114
+4
+4% +$955 ﹤0.01% 993
2023
Q4 		$26K Buy
110
+26
+31% +$5.11K ﹤0.01% 1044
2023
Q3 		$16.5K Sell
84
-48
-36% -$9.85K ﹤0.01% 1156
2023
Q2 		$27.8K Buy
132
+65
+97% +$12.9K ﹤0.01% 932
2023
Q1 		$13.5K Sell
67
-13
-16% -$2.95K ﹤0.01% 1267
2022
Q4 		$17.4K Sell
80
-41
-34% -$8.95K ﹤0.01% 1133
2022
Q3 		$24K Buy
121
+40
+49% +$8.63K ﹤0.01% 906
2022
Q2 		$17K Buy
81
+9
+13% +$2.2K ﹤0.01% 1030
2022
Q1 		$20K Sell
72
-13
-15% -$4.01K ﹤0.01% 996
2021
Q4 		$32K Sell
85
-8
-9% -$3.11K ﹤0.01% 861
2021
Q3 		$38K Sell
93
-5
-5% -$2.08K 0.01% 520
2021
Q2 		$36K Buy
98
+10
+11% +$3.34K 0.01% 572
2021
Q1 		$26K Buy
88
+15
+21% +$4.17K 0.01% 654
2020
Q4 		$18K Buy
73
+3
+4% +$714 ﹤0.01% 714
2020
Q3 		$16K Buy
70
+3
+4% +$623 ﹤0.01% 686
2020
Q2 		$12K Sell
67
-17
-20% -$2.71K ﹤0.01% 766
2020
Q1 		$11K Buy
84
+8
+11% +$1.2K ﹤0.01% 718
2019
Q4 		$12K Hold
76
– – ﹤0.01% 870
2019
Q3 		$10K Buy
76
+17
+29% +$2.28K ﹤0.01% 897
2019
Q2 		$8K Hold
59
– – ﹤0.01% 944
2019
Q1 		$8K Hold
59
– – ﹤0.01% 948
2018
Q4 		$6K Buy
+59
New +$7.39K ﹤0.01% 956

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lindbrook Capital's CRL Position: Q1 2025 in Review

Lindbrook Capital increased its Charles River Laboratories (CRL) stake by 201% in Q1 2025, buying an estimated $54K and bringing the position to 482 shares worth $72.6K. The position accounts for 0.01% of the portfolio, ranked #824.

Lindbrook Capital first reported a position in CRL in Q4 2018 and has held it in 26 quarters since. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Lindbrook Capital held 482 shares of Charles River Laboratories worth $72.6K as of Q1 2025.
  • Lindbrook Capital bought 322 Charles River Laboratories shares in Q1 2025, an estimated $54K.
  • Charles River Laboratories made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #824 holding.
  • Lindbrook Capital first reported a position in Charles River Laboratories in Q4 2018 and has held it in 26 quarters since.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.